KBC Group
TERN

KBC Group’s Terns Pharmaceuticals TERN Stock Holding History

KBC Group’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$89K Buy
+1,683
New +$69.1K ﹤0.01% 1396

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

KBC Group's TERN Position: Q1 2026 in Review

KBC Group opened a new position in Terns Pharmaceuticals (TERN) in Q1 2026: 1,683 shares worth $89K. The stake represents ﹤0.01% of the portfolio and ranks #1396 among its holdings.

317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • KBC Group held 1,683 shares of Terns Pharmaceuticals worth $89K as of Q1 2026.
  • Terns Pharmaceuticals was a new KBC Group position in Q1 2026.
  • Terns Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1396 holding.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.